AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

30 recruiting trials

for B-ALL

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site📍 St Louis Washington University School of Medicine Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site📍 Beijing Hebei Senlang Biotechnology Inc., Ltd. · Tests: S1904 CD19 CAR-T CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site📍 Madison University of Wisconsin, Madison · Tests: TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085Phase 3231 sites📍 Birmingham📍 Mobile📍 Anchorage Children's Oncology Group · Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites📍 Beijing📍 Beijing📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: pCAR-19B cells A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites📍 Toronto📍 Copenhagen📍 Aarhus Nord Merck Sharp & Dohme LLC · Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) NCT07476729Phase 321 sites📍 Vienna📍 Ghent📍 Prague Charite University, Berlin, Germany · Tests: Inotuzumab ozogamicin (INO), Blinatumomab Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029Phase 29 sites📍 Duarte📍 Stanford📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Obecabtagene Autoleucel Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site📍 Beijing Peking University People's Hospital · Tests: Senl_B19 autologous CAR-T (S1904) treatment Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia NCT06793241EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites📍 Hefei📍 Chongqing📍 Guangzhou Juventas Cell Therapy Ltd. · Tests: single dose of CNCT19 Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites📍 Tübingen📍 Tübingen University Hospital Tuebingen · Tests: CAR-T cells targeting CD19 and CD22 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885Phase 1, Phase 22 sites📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: CAR19TIF cells, Fludarabine, Cyclophosphamide A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site📍 Hangzhou He Huang · Tests: CTA101 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant NCT06059391Phase 23 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hema… CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. NCT06752785Phase 11 site📍 Guangzhou Guangzhou Women and Children's Medical Center · Tests: CAR-T Therapy Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL NCT06880913Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Nanobody-Based CD19/CD22 Tandem Dual CAR-T CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291Phase 31 site📍 Beijing Peking University People's Hospital · Tests: CAR-T, DLI Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022Phase 19 sites📍 Birmingham📍 Duarte📍 Atlanta Ascentage Pharma Group Inc. · Tests: Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T cells, Venetoclax, Olverembatinib UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site📍 Aurora University of Colorado, Denver · Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT NCT03810196NA1 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies NCT04532281EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: Murine CD19 CAR-T cells

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy